Compare BridgeBio Pharma Inc (BBIO) vs Manhattan Associates Inc (MANH) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

MANH trades at $195.23, up 2.41% in the last 24 hours, with a bullish technical outlook supported by a golden cross and strong momentum indicators. The company reported Q2 2026 EPS of $1.39, beating estimates, and maintains robust profitability with an 18.67% net income margin. However, high valuation ratios like a P/E of 56.07 and ongoing legal investigations pose concerns.

Outlook is positive with an 80% analyst buy rating and a $210.33 consensus price target, implying ~8% upside. Key risks include elevated valuation multiples and fiduciary duty investigations by Rosen Law Firm, which could impact investor confidence near-term.